Melasma insulin resistance: Is there a proven link?

Current evidence does not establish that melasma causes, predicts, or results from insulin resistance. A few small observational studies raise questions about metabolic health in people with melasma, but they cannot show which came first or whether one caused the other. One prominent case-control paper was retracted. Melasma by itself is therefore not a reason to request glucose or insulin testing. A metabolic evaluation can still be appropriate when a person has established risk factors or symptoms, regardless of pigmentation.

This distinction matters because a brown facial patch is visible while insulin resistance usually is not. It is easy to turn a possible association into a self-diagnosis. The more accurate approach is to evaluate melasma as a skin condition and assess metabolic risk on its own clinical merits.

Is melasma associated with insulin resistance?#

The association is unproven. The available research is too limited and too methodologically weak to establish that people with melasma have more insulin resistance than comparable people without it. It also does not show that lowering blood glucose fades melasma.

Melasma is an acquired pigment disorder that typically causes symmetrical brown or gray-brown patches on the face. Insulin resistance means the body's cells do not respond to insulin as well as they should, which can contribute to higher blood glucose. These are separate definitions, and neither definition implies the other.

The most useful way to read this literature is by study design rather than by a headline. A cross-sectional study can count how many participants have two conditions at one point in time. It cannot determine whether either condition caused the other. A case-control study can compare groups, but its conclusions depend on appropriate matching, valid measurements, and trustworthy data.

The 2025 Portuguese Journal of Dermatology and Venereology study is often easy to overread. It reported that 29.3% of 58 women with melasma met at least three metabolic-syndrome criteria. Without a control group matched for age, body composition, menopause status, and other risk factors, that percentage cannot tell us whether melasma added risk.

The 2024 Annals of Dermatology study compared plasma metabolites in 20 women with melasma and 21 controls. It found exploratory differences in amino-acid, lipid, and carbohydrate-related metabolites. Metabolomics can generate a hypothesis, but it is not equivalent to fasting glucose, A1C, an oral glucose tolerance test, or a clinical diagnosis of insulin resistance.

Most importantly, the 2022 article titled “Metabolic Syndrome in Melasma: A case-control study” is marked retracted in PubMed and by its publisher. Retracted findings should not be counted as positive evidence. The combination of one uncontrolled prevalence study, one small exploratory laboratory study, and one retraction leaves the overall evidence quality very low.

For a broader explanation of how sustained high blood sugar may affect skin proteins over time, read how glycation relates to skin aging. Glycation is a different question from whether melasma identifies insulin resistance.

Why can melasma and metabolic risk appear together without causation?#

Shared background factors can create an association even when neither condition causes the other. Age, body composition, hormonal transitions, medication use, pregnancy history, sun exposure, and access to medical care can all differ between study groups. Small studies cannot reliably separate every one of these influences.

Melasma has well-recognized links to ultraviolet and visible light, genetic susceptibility, pregnancy, and hormonal exposures. The American Academy of Dermatology (AAD) also notes that some medications and stress may act as triggers. These established considerations remain more clinically useful than an unconfirmed metabolic theory.

Insulin resistance has its own risk pattern. NIDDK lists factors such as age 35 or older, overweight or obesity, a parent or sibling with diabetes, physical inactivity, a history of gestational diabetes, and polycystic ovary syndrome. Some of those factors may be common in the same population that develops melasma. That overlap can produce confounding, meaning a third factor helps explain an apparent relationship.

A visible skin finding can also increase health-care contact. Someone seeking care for melasma may have blood pressure, waist circumference, or laboratory values checked more often than someone who does not see a clinician. This form of detection bias can make two conditions look more tightly connected than they are.

Who should discuss metabolic evaluation with a clinician?#

The discussion should be driven by recognized diabetes and cardiovascular risk factors, not by melasma alone. A primary care clinician can combine age, medical history, family history, blood pressure, body composition, pregnancy history, medications, and prior laboratory results to decide whether testing is appropriate.

It is reasonable to raise metabolic evaluation at a routine visit if one or more of these situations applies:

• you have overweight or obesity plus another diabetes risk factor;
• a parent or sibling has type 2 diabetes;
• you previously had gestational diabetes or delivered a baby weighing 9 pounds or more;
• you have polycystic ovary syndrome, high blood pressure, abnormal cholesterol or triglycerides, cardiovascular disease, or physical inactivity;
• a previous fasting glucose or A1C result was elevated;
• you have symptoms such as increased thirst, frequent urination, unexplained weight loss, or unusual fatigue that need clinical assessment.

NIDDK explains that clinicians diagnose prediabetes with blood glucose tests, including A1C, fasting plasma glucose, or an oral glucose tolerance test. Tests used mainly in research may estimate insulin resistance directly, but routine clinical decisions usually focus on validated glucose measures and the person's full risk profile.

Melasma without these concerns does not create a special need for fasting insulin, continuous glucose monitoring, or repeated glucose testing. Testing can carry costs and can generate borderline results that need interpretation. The right question is not “Which metabolic test does this patch require?” but “Does my overall health history meet a recognized reason to screen?”

Does this change melasma care?#

No—the standard melasma plan still starts with diagnosis, light protection, and dermatology-guided treatment when desired. Metabolic speculation should not delay evaluation of a new or changing patch, and attempts to “fix insulin” should not replace established pigmentation care.

The AAD recommends broad-spectrum, water-resistant sunscreen with SPF 30 or higher, along with shade and a wide-brimmed hat. For melasma, the AAD notes that tinted sunscreen containing iron oxide can help protect against visible light as well as ultraviolet exposure. Gentle products matter because irritation can make dark patches more noticeable.

Our focused guide to sunscreen SPF and PA ratings explains protection labels, while home care for melasma and dark spots covers topical routines. Those articles own the treatment question; the metabolic evidence does not justify a special diet, supplement, glucose device, or insulin-lowering strategy for melasma.

A dermatologist should assess pigmentation that is new, changing, one-sided, irregular in color or border, raised, itchy, painful, or bleeding. A clinician can distinguish melasma from post-inflammatory hyperpigmentation, sun spots, medication-related pigmentation, and lesions that require closer examination. If procedural options are being considered, melasma treatment expectations and limitations provide useful questions even when care is obtained in the United States.

✨ In short#

The claimed melasma-insulin resistance link is not established. Current studies can generate hypotheses, but they cannot show that melasma causes insulin resistance, that insulin resistance causes melasma, or that a facial patch should trigger metabolic testing. One frequently cited positive study was retracted, which further lowers confidence.

Sources#

• American Academy of Dermatology: Melasma—diagnosis and treatment
• NIDDK: Insulin Resistance and Prediabetes
• Steiner and Silva, 2025: Assessment of metabolic syndrome in patients diagnosed with melasma
• Wang et al., 2024: Plasma Metabolomics Indicates Potential Biomarkers and Abnormal Metabolic Pathways in Female Melasma Patients
• PubMed retraction record: Metabolic Syndrome in Melasma—A case-control study